Test Price
2,800 AED✅ Home Collection Available
ERCC4 Gene XFE Progeroid Syndrome Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM–11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
This advanced next‑generation sequencing (NGS) test for the ERCC4 gene delivers 99.9% diagnostic accuracy per ISO standards. Recommended for children presenting with features of XFE progeroid syndrome or with a family history, it is performed via home collection with post-result genetic counselling.
Test Overview & Methodology
The ERCC4 (XPF) gene NGS test is a next‑generation sequencing analysis that detects pathogenic mutations causing XFE progeroid syndrome, a severe DNA‑repair disorder leading to premature aging and cancer predisposition. It yields a definitive molecular diagnosis and empowers paediatricians, clinical geneticists, and oncologists to tailor surveillance and management in accordance with DHA protocols.
| Feature | Our ERCC4 NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision / Sensitivity | 99.9% single‑gene resolution | Broad coverage with lower per‑gene depth |
| Methodology | Targeted NGS (Illumina NovaSeq, validated bioinformatics) | Whole exome capture + variant filtering |
| Turnaround Time | 3–4 weeks | 8–12 weeks |
| Clinical Utility | Direct diagnostic answer for suspected XFE progeroid syndrome | May require secondary confirmation |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I witness the profound uncertainty families face when confronted with features of a progeroid syndrome. This test offers a clear genetic explanation, allowing us to establish an evidence‑based care plan, initiate cancer screening, and provide compassionate genetic counselling.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Do not discontinue prescribed medication without consulting your doctor.
Always consult your healthcare provider before making any changes to your child’s medication regimen. The genetic test result should be interpreted together with your physician to ensure safe management.
Exclusion Criteria & Emergency Red Flags
- This test is not suitable for asymptomatic individuals without a clinical suspicion or family history of XFE progeroid syndrome.
- Pre‑test genetic counselling and written informed consent are mandatory; testing of minors requires parental/guardian consent and a referral from a DHA‑licensed specialist.
- ER Red Flags: If the patient develops acute respiratory distress, unexplained high fever, rapid weight loss, severe dehydration, or signs of infection, immediately visit the nearest emergency department—do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the ERCC4 gene test, and who should consider it?
Answer: The ERCC4 gene test uses next‑generation sequencing to detect mutations causing XFE progeroid syndrome, a rare premature aging and cancer predisposition disorder. It is recommended for children with growth failure, characteristic facial features, or sun‑sensitive skin.
2. How is the sample collected, and what is the turnaround time?
Answer: A blood sample, one drop on an FTA card, or previously extracted DNA is collected at home or clinic; results are ready in 3–4 weeks with ISO‑certified accuracy and include genetic counselling support.
3. What do the results mean for my child’s future health?
Answer: A positive result confirms XFE progeroid syndrome, enabling early cancer surveillance and multidisciplinary care. A negative result excludes the syndrome, but genetic counselling may suggest further testing if clinical suspicion remains high.
UAE Regulatory & Data Privacy Adherence
Your Privacy & Safety Are Protected by UAE Law
This test is performed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted and handled exclusively within the UAE regulatory framework.
Clinical & Logistical Metadata
| Test Name | ERCC4 Gene XFE Progeroid Syndrome NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood, FTA card, or extracted DNA |
| Methodology Used | Targeted Next‑Generation Sequencing (NGS) – Illumina NovaSeq platform |
| ICD-10-CM Code | E34.8 |
| LOINC Code | 81319-2 |
| DHA Facility License & Laboratory Address | License No. 1143 · Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians